
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Fanconi syndrome primary prevention
Introduction
Overview
Overview
Prevention of Fanconi syndrome mostly depends on early diagnosis, treatment and management of potential underlying diseases and/or preventing the toxicity of the exposure to exogenous precipitating factors.
Primary Prevention
Primary Prevention
Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome’s progression or even onset[1][2][3]:
- Cystinosis medical therapy
- Wilson disease medical therapy
- and to a lesser extent Tyrosinemia medical therapy ( late onset Tyrosinemia lead to best results)
Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome’s progression or even onset:
- Galactosemia, Galctose consumption restriction
- Hereditary fructose intolerance, Fructose consumption restriction
- Tyrosinemia, tyrosine/phenylalanine consumption restriction
- Any precipitating drug or heavy metal exposure restriction or adjustment, including: Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides, tetracyclines, cadmium and lead
References
References
- ↑ Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R; et al. (2014). “Long-term outcomes of patients with Wilson disease in a large Austrian cohort”. Clin Gastroenterol Hepatol. 12 (4): 683–9. doi:10.1016/j.cgh.2013.09.025. PMID 24076416.
- ↑ Emma F, Nesterova G, Langman C, Labbé A, Cherqui S, Goodyer P; et al. (2014). “Nephropathic cystinosis: an international consensus document”. Nephrol Dial Transplant. 29 Suppl 4: iv87–94. doi:10.1093/ndt/gfu090. PMC 4158338. PMID 25165189.
- ↑ van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V; et al. (1994). “Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment”. Hepatology. 20 (5): 1187–91. PMID 7927251.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vahid Eidkhani, M.D.
